Gabriel Cassinelli Petersen1, Michelle Roytman2, Gloria C Chiang2, Yi Li2, Marc L Gordon3, Ana M Franceschi4. 1. Department of Radiology, Yale School of Medicine, New Haven, Connecticut. 2. Department of Radiology, New York-Presbyterian Hospital/Weill Cornell Medical College, New York. 3. Departments of Neurology and Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, The Litwin-Zucker Research Center, Feinstein Institutes for Medical Research, Manhasset. 4. Neuroradiology Division, Department of Radiology, Northwell Health/Donald and Barbara Zucker School of Medicine, Lenox Hill Hospital, New York, New York, USA.
Abstract
PURPOSE OF REVIEW: This article reviews tau PET imaging with an emphasis on first-generation and second-generation tau radiotracers and their application in neurodegenerative disorders, including Alzheimer's disease and non-Alzheimer's disease tauopathies. RECENT FINDINGS: Tau is a critical protein, abundant in neurons within the central nervous system, which plays an important role in maintaining microtubules by binding to tubulin in axons. In its abnormal hyperphosphorylated form, accumulation of tau has been linked to a variety of neurodegenerative disorders, collectively referred to as tauopathies, which include Alzheimer's disease and non-Alzheimer's disease tauopathies [e.g., corticobasal degeneration (CBD), argyrophilic grain disease, progressive supranuclear palsy (PSP), and Pick's disease]. A number of first-generation and second-generation tau PET radiotracers have been developed, including the first FDA-approved agent [18F]-flortaucipir, which allow for in-vivo molecular imaging of underlying histopathology antemortem, ultimately guiding disease staging and development of disease-modifying therapeutics. SUMMARY: Tau PET is an emerging imaging modality in the diagnosis and staging of tauopathies.
PURPOSE OF REVIEW: This article reviews tau PET imaging with an emphasis on first-generation and second-generation tau radiotracers and their application in neurodegenerative disorders, including Alzheimer's disease and non-Alzheimer's disease tauopathies. RECENT FINDINGS: Tau is a critical protein, abundant in neurons within the central nervous system, which plays an important role in maintaining microtubules by binding to tubulin in axons. In its abnormal hyperphosphorylated form, accumulation of tau has been linked to a variety of neurodegenerative disorders, collectively referred to as tauopathies, which include Alzheimer's disease and non-Alzheimer's disease tauopathies [e.g., corticobasal degeneration (CBD), argyrophilic grain disease, progressive supranuclear palsy (PSP), and Pick's disease]. A number of first-generation and second-generation tau PET radiotracers have been developed, including the first FDA-approved agent [18F]-flortaucipir, which allow for in-vivo molecular imaging of underlying histopathology antemortem, ultimately guiding disease staging and development of disease-modifying therapeutics. SUMMARY: Tau PET is an emerging imaging modality in the diagnosis and staging of tauopathies.
Authors: Marta Marquié; Michael Siao Tick Chong; Alejandro Antón-Fernández; Eline E Verwer; Nil Sáez-Calveras; Avery C Meltzer; Prianca Ramanan; Ana C Amaral; Jose Gonzalez; Marc D Normandin; Matthew P Frosch; Teresa Gómez-Isla Journal: Acta Neuropathol Date: 2017-06-13 Impact factor: 17.088
Authors: Hanna Cho; Sang Won Seo; Jae Yong Choi; Hye Sun Lee; Young Hoon Ryu; Myung Sik Lee; Duk L Na; Hee Jin Kim; Chul Hyoung Lyoo Journal: Neurobiol Aging Date: 2018-02-21 Impact factor: 4.673
Authors: Michael Schöll; Samuel N Lockhart; Daniel R Schonhaut; James P O'Neil; Mustafa Janabi; Rik Ossenkoppele; Suzanne L Baker; Jacob W Vogel; Jamie Faria; Henry D Schwimmer; Gil D Rabinovici; William J Jagust Journal: Neuron Date: 2016-03-02 Impact factor: 17.173
Authors: Kerstin Sander; Tammaryn Lashley; Priya Gami; Thibault Gendron; Mark F Lythgoe; Jonathan D Rohrer; Jonathan M Schott; Tamas Revesz; Nick C Fox; Erik Årstad Journal: Alzheimers Dement Date: 2016-02-15 Impact factor: 21.566
Authors: Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566
Authors: Marta Marquié; Eline E Verwer; Avery C Meltzer; Sally Ji Who Kim; Cinthya Agüero; Jose Gonzalez; Sara J Makaretz; Michael Siao Tick Chong; Prianca Ramanan; Ana C Amaral; Marc D Normandin; Charles R Vanderburg; Stephen N Gomperts; Keith A Johnson; Matthew P Frosch; Teresa Gómez-Isla Journal: Acta Neuropathol Commun Date: 2017-10-19 Impact factor: 7.801
Authors: Leonie Beyer; Alexander Nitschmann; Henryk Barthel; Thilo van Eimeren; Marcus Unterrainer; Julia Sauerbeck; Ken Marek; Mengmeng Song; Carla Palleis; Gesine Respondek; Jochen Hammes; Michael T Barbe; Özgür Onur; Frank Jessen; Dorothee Saur; Matthias L Schroeter; Jost-Julian Rumpf; Michael Rullmann; Andreas Schildan; Marianne Patt; Bernd Neumaier; Olivier Barret; Jennifer Madonia; David S Russell; Andrew W Stephens; Sigrun Roeber; Jochen Herms; Kai Bötzel; Johannes Levin; Joseph Classen; Günter U Höglinger; Peter Bartenstein; Victor Villemagne; Alexander Drzezga; John Seibyl; Osama Sabri; Matthias Brendel Journal: Eur J Nucl Med Mol Imaging Date: 2020-04-21 Impact factor: 9.236
Authors: Andre Mueller; Santiago Bullich; Olivier Barret; Jennifer Madonia; Mathias Berndt; Caroline Papin; Audrey Perrotin; Norman Koglin; Heiko Kroth; Andrea Pfeifer; Gilles Tamagnan; John P Seibyl; Kenneth Marek; Susan De Santi; Ludger M Dinkelborg; Andrew W Stephens Journal: J Nucl Med Date: 2019-11-11 Impact factor: 11.082